GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ZYUS Life Sciences Corp (TSXV:ZYUS) » Definitions » EV-to-EBIT

ZYUS Life Sciences (TSXV:ZYUS) EV-to-EBIT : -1.79 (As of May. 27, 2024)


View and export this data going back to 2023. Start your Free Trial

What is ZYUS Life Sciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ZYUS Life Sciences's Enterprise Value is C$76.22 Mil. ZYUS Life Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$-42.63 Mil. Therefore, ZYUS Life Sciences's EV-to-EBIT for today is -1.79.

The historical rank and industry rank for ZYUS Life Sciences's EV-to-EBIT or its related term are showing as below:

TSXV:ZYUS' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.73   Med: -1.98   Max: -1.55
Current: -1.79

During the past 3 years, the highest EV-to-EBIT of ZYUS Life Sciences was -1.55. The lowest was -8.73. And the median was -1.98.

TSXV:ZYUS's EV-to-EBIT is ranked worse than
100% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.155 vs TSXV:ZYUS: -1.79

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. ZYUS Life Sciences's Enterprise Value for the quarter that ended in Dec. 2023 was C$67.72 Mil. ZYUS Life Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$-42.63 Mil. ZYUS Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -62.96%.


ZYUS Life Sciences EV-to-EBIT Historical Data

The historical data trend for ZYUS Life Sciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZYUS Life Sciences EV-to-EBIT Chart

ZYUS Life Sciences Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBIT
- - -1.50

ZYUS Life Sciences Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only - - -4.90 -4.19 -1.50

Competitive Comparison of ZYUS Life Sciences's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ZYUS Life Sciences's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ZYUS Life Sciences's EV-to-EBIT falls into.



ZYUS Life Sciences EV-to-EBIT Calculation

ZYUS Life Sciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=76.218/-42.633
=-1.79

ZYUS Life Sciences's current Enterprise Value is C$76.22 Mil.
ZYUS Life Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-42.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ZYUS Life Sciences  (TSXV:ZYUS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

ZYUS Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-42.633/67.71666
=-62.96 %

ZYUS Life Sciences's Enterprise Value for the quarter that ended in Dec. 2023 was C$67.72 Mil.
ZYUS Life Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-42.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ZYUS Life Sciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of ZYUS Life Sciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


ZYUS Life Sciences (TSXV:ZYUS) Business Description

Traded in Other Exchanges
Address
407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
ZYUS Life Sciences Corp is a next-generation life sciences company engaged in scientific research and development in phyto-therapeutics, including cannabinoid and protein-based formulations. It is committed to delivering high-quality standardized therapeutic formulations that comply with Good Manufacturing Practices (GMP) to provide targeted relief for patients in Canada and globally.
Executives
John Michael Hyshka Senior Officer

ZYUS Life Sciences (TSXV:ZYUS) Headlines

No Headlines